Lexicon Pharmaceuticals, Inc. (LXRX)
NASDAQ: LXRX · Real-Time Price · USD
1.230
-0.120 (-8.89%)
At close: Jul 18, 2025, 4:00 PM
1.240
+0.010 (0.81%)
After-hours: Jul 18, 2025, 6:27 PM EDT
Lexicon Pharmaceuticals Market Cap
Lexicon Pharmaceuticals has a market cap or net worth of $446.71 million as of July 18, 2025. Its market cap has increased by 8.32% in one year.
Market Cap
446.71M
Enterprise Value
365.40M
1-Year Change
8.32%
Ranking
Category
Stock Price
$1.23
Market Cap Chart
Since April 7, 2000, Lexicon Pharmaceuticals's market cap has decreased from $890.90M to $446.71M, a decrease of -49.86%. That is a compound annual growth rate of -2.69%.
Market Cap History
Date | Market Cap | % Change |
---|---|---|
Jul 17, 2025 | 490.30M | 83.56% |
Dec 31, 2024 | 267.10M | -28.72% |
Dec 29, 2023 | 374.70M | 3.94% |
Dec 30, 2022 | 360.50M | -38.54% |
Dec 31, 2021 | 586.60M | 45.99% |
Dec 31, 2020 | 401.80M | -8.89% |
Dec 31, 2019 | 441.00M | -37.30% |
Dec 31, 2018 | 703.30M | -32.58% |
Dec 29, 2017 | 1.04B | -27.50% |
Dec 30, 2016 | 1.44B | 4.32% |
Dec 31, 2015 | 1.38B | 194.45% |
Dec 31, 2014 | 468.40M | -49.30% |
Dec 31, 2013 | 923.80M | -18.41% |
Dec 31, 2012 | 1.13B | 159.94% |
Dec 30, 2011 | 435.60M | -10.39% |
Dec 31, 2010 | 486.10M | 62.74% |
Dec 31, 2009 | 298.70M | 55.98% |
Dec 31, 2008 | 191.50M | -53.80% |
Dec 31, 2007 | 414.50M | 50.51% |
Dec 29, 2006 | 275.40M | 16.89% |
Dec 30, 2005 | 235.60M | -52.10% |
Dec 31, 2004 | 491.90M | 33.02% |
Dec 31, 2003 | 369.80M | 49.35% |
Dec 31, 2002 | 247.60M | -58.67% |
Dec 31, 2001 | 599.10M | -25.13% |
View and export this data all the way back to 2000. Sign Up Today.
Market Capitalization
Market capitalization, also called net worth, is the total value of all of a company's outstanding shares. It is calculated by multiplying the stock price by the number of shares outstanding.
Formula: Market Cap = Stock Price * Shares Outstanding
Full DefinitionRelated Stocks
Company | Market Cap |
---|---|
Eli Lilly and Company | 709.03B |
Johnson & Johnson | 396.47B |
AbbVie | 336.64B |
Novo Nordisk | 301.36B |
UnitedHealth Group | 265.33B |
Novartis AG | 233.75B |
Abbott Laboratories | 229.21B |
AstraZeneca | 217.77B |